Connection
David Raben to Administration, Oral
This is a "connection" page, showing publications David Raben has written about Administration, Oral.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.040 |
|
|
|
-
Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46.
Score: 0.040